Get the Stockscreener App
12.26
2.34%
0.28
Pre-market:
12.59
0.33
+2.69%
Inhibrx Biosciences Inc stock is traded at $12.26, with a volume of 41,757.
It is up +2.34% in the last 24 hours and down -13.78% over the past month.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
See More
Previous Close:
$11.98
Open:
$11.85
24h Volume:
41,757
Relative Volume:
0.40
Market Cap:
$164.74M
Revenue:
$1.80M
Net Income/Loss:
$1.76B
P/E Ratio:
0.1033
EPS:
118.674
Net Cash Flow:
$-149.23M
1W Performance:
+6.89%
1M Performance:
-13.78%
6M Performance:
-20.23%
1Y Performance:
-64.04%
1-Day Range:
$11.84
$12.82
1-Week Range:
$11.22
$12.82
52-Week Range:
$10.80
$34.75
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Name
Inhibrx Biosciences Inc
Sector
Industry
Phone
(858) 795-4220
Address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
12.26 | 164.74M | 1.80M | 1.76B | -149.23M | 118.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-24 | Initiated | JMP Securities | Mkt Perform |
| Jan-23-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Mar-16-22 | Initiated | SMBC Nikko | Outperform |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Evercore ISI | Outperform |
View All
Inhibrx Biosciences Inc Stock (INBX) Latest News
(INBX) On The My Stocks Page - news.stocktradersdaily.com
Inhibrx Biosciences reshuffles leadership, appoints new CSO and President By Investing.com - Investing.com South Africa
Inhibrx Biosciences reshuffles leadership, appoints new CSO and President - Investing.com India
Inhibrx Biosciences Announces Departure Of CSO And Appointments Of New CSO And President - TradingView
Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President - PR Newswire
How the (INBX) price action is used to our Advantage - news.stocktradersdaily.com
JMP maintains Market Perform on Inhibrx stock post-earnings - Investing.com India
Inhibrx Biosciences, Inc. SEC 10-K Report - TradingView
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Yahoo
Long Term Trading Analysis for (INBX) - Stock Traders Daily
When (INBX) Moves Investors should Listen - Stock Traders Daily
A closer look at Inhibrx Biosciences Inc (INBX)’s stock price trends - US Post News
When the Price of (INBX) Talks, People Listen - Stock Traders Daily
BlackRock, Inc. Increases Stake in Inhibrx Biosciences Inc. - GuruFocus.com
(INBX) Trading Signals - Stock Traders Daily
Inhibrx reports promising ozekibart trial results - MSN
Inhibrx's SWOT analysis: oncology biotech stock faces pivotal year ahead - MSN
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 - GuruFocus.com
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer – Company Announcement - Financial Times
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer - PR Newswire
How to Take Advantage of moves in (INBX) - Stock Traders Daily
Inhibrx Biosciences enters $150M loan facility - MSN
Regeneron, Illumina invest in Truveta; Inhibrx Bio’s $150M loan - Endpoints News
Inhibrx Biosciences, Inc. Announces Loan Agreement with Oxford Finance LLC - Marketscreener.com
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance - StreetInsider.com
(INBX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
How To Trade (INBX) - Stock Traders Daily
Inhibrx's SWOT analysis: biotech stock faces pivotal year amid clinical trials - Investing.com India
(INBX) Trading Report - Stock Traders Daily
Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year By Investing.com - Investing.com Nigeria
Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year - Investing.com
2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy - News & Insights
Inhibrx Biosciences director Jon Faiz Kayyem buys $1.52m in stock - Investing.com Nigeria
Trend Tracker for (INBX) - Stock Traders Daily
The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares - Yahoo Finance
institutional investors of Inhibrx Biosciences, Inc. (NASDAQ:INBX) must be disappointed after last week's 15% drop - Simply Wall St
Perceptive Advisors LLC Bolsters Stake in Inhibrx Biosciences Inc - GuruFocus.com
Inhibrx Biosciences Inc (INBX) Quarterly 10-Q Report - Quartzy
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PR Newswire
Inhibrx Biosciences Inc. (INBX) Quarterly 10-Q Report - Quartzy
Wilson Sonsini Knocks Out Claims Against Inhibrx Biosciences in Trade Secrets Verdict - Law.com
Inhibrx Biosciences’ Trade Secret Case - Global Legal Chronicle
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha
Inhibrx Biosciences Inc Stock (INBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):